Company:  EXELIXIS, INC. (EXEL)
Form Type:  8-K
Filing Date:  2/7/2012 
CIK:  0000939767 
Address:  210 E. GRAND AVE 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 837-7000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$3.41  
Change: 
-0.045 (-1.30%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$662.90M
Description of Business
Exelixis, Inc. (�Exelixis,� �we,� �our� or �us�) is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Our two most advanced assets, COMETRIQ� (cabozantinib), our wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib (GDC-0973/XL518), a potent, highly selective inhibitor of MEK, which we out-licensed to Genentech, Inc. (a wholly-owned member of the Roche Group), or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Top-line results from four of these pivotal trials are expected in 2014. We are focusing our proprietary resources and development and commercialization efforts primarily on COMETRIQ (cabozantinib), which was approved on November 29, 2012, by the U.S. Food and Drug Administration, or FDA, for the treatment of progressive, metastatic medullary thyroid cancer, or MTC, in the United States, where it became commercially available in late January 2013.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02. Departure of Directors or Certain Officers; ...
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURE
    Exhibit Index
  EXHIBIT 10.1
BROKERAGE PARTNERS